Who are vehicle of bimatoprost solution 0.03 %'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vyzulta, Travatan, Xalatan, Hemabate, Enzaprost, Travatan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vehicle-of-bimatoprost-solution-0-03.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

vehicle of bimatoprost solution 0.03 % — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

vehicle of bimatoprost solution 0.03 % (vehicle of bimatoprost solution 0.03 %) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog. Area: Ophthalmology.

phase 3 Prostaglandin analog Prostaglandin F2-alpha receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

vehicle of bimatoprost solution 0.03 % (vehicle of bimatoprost solution 0.03 %) — Allergan. Bimatoprost is a prostaglandin analog that mimics the action of prostaglandin F2-alpha, leading to increased uveoscleral outflow and decreased intraocular pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
vehicle of bimatoprost solution 0.03 % TARGET	vehicle of bimatoprost solution 0.03 %	Allergan	phase 3	Prostaglandin analog	Prostaglandin F2-alpha receptor
Vyzulta	LATANOPROSTENE BUNOD	Bausch Health	marketed		Prostaglandin F2-alpha receptor	2017-01-01
Travatan	TRAVOPROST		marketed	Prostaglandin Analog [EPC]	Prostaglandin F2-alpha receptor	2001-01-01
Xalatan	LATANOPROST	Thea Pharma	marketed	Prostaglandin Analog [EPC]	Prostaglandin F2-alpha receptor	1996-01-01
Hemabate	CARBOPROST	Pfizer	marketed	Prostaglandin Analog	Prostaglandin F2-alpha receptor	1979-01-01
Enzaprost	DINOPROST	Pfizer	marketed	dinoprost	Prostaglandin F2-alpha receptor	1976-01-01
Travatan	Travatan	Alcon Research	marketed		Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog class)

Allergan · 3 drugs in this class
AbbVie · 2 drugs in this class
Bnai Zion Medical Center · 1 drug in this class
Ibis Reproductive Health · 1 drug in this class
Ocuwize LTD · 1 drug in this class
Shaare Zedek Medical Center · 1 drug in this class
University Medical Centre Maribor · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class
University of Pennsylvania · 1 drug in this class
Wolfson Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). vehicle of bimatoprost solution 0.03 % — Competitive Intelligence Brief. https://druglandscape.com/ci/vehicle-of-bimatoprost-solution-0-03. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab